Recombinant Protein-Based Nanoparticles: Elucidating Their Inflammatory Effects In Vivo and Their Potential as a New Therapeutic Format

Bacterial inclusion bodies (IBs) are protein-based nanoparticles of a few hundred nanometers formed during recombinant protein production processes in different bacterial hosts. IBs contain active protein in a mechanically stable nanostructured format that has been broadly characterized, showing promising potential in different fields such as tissue engineering, protein replacement therapies, cancer, and biotechnology. For immunomodulatory purposes, however, the interference of the format immunogenic properties—intrinsic to IBs—with the specific effects of the therapeutic protein is still an uncovered gap. For that, active and inactive forms of the catalytic domain of a matrix metalloproteinase-9 (MMP-9 and mutMMP-9, respectively) have been produced as IBs and compared with the soluble form for dermal inflammatory effects in mmp9 knock-out mice. After protein injections in air-pouches in the mouse model, MMP-9 IBs induce local neutrophil recruitment and increase pro-inflammatory chemokine levels, lasting for at least two days, whereas the effects triggered by the soluble MMP-9 format fade out after 3 h. Interestingly, the IB intrinsic effects (mutMMP-9 IBs) do not last more than 24 h. Therefore, it may be concluded that IBs could be used for the delivery of therapeutic proteins, such as immunomodulating proteins while preserving their stability in the specific tissue and without triggering important unspecific inflammatory responses due to the protein format.

[1]  Dany Qumsiyeh,et al.  Profit , 2020, Placing Papers.

[2]  A. Villaverde,et al.  Nanostructured recombinant protein particles raise specific antibodies against the nodavirus NNV coat protein in sole. , 2020, Fish & shellfish immunology.

[3]  S. Schwartz,et al.  The Biological Potential Hidden in Inclusion Bodies , 2020, Pharmaceutics.

[4]  A. Saneja,et al.  Bacterial Inclusion Bodies: A Treasure Trove of Bioactive Proteins. , 2020, Trends in biotechnology.

[5]  U. Rinas,et al.  Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies , 2019, Advanced science.

[6]  O. Spadiut,et al.  Perspectives of inclusion bodies for bio-based products: curse or blessing? , 2018, Applied Microbiology and Biotechnology.

[7]  U. Rinas,et al.  Bacterial inclusion bodies are industrially exploitable amyloids , 2018, FEMS microbiology reviews.

[8]  N. Ferrer-Miralles,et al.  A new approach to obtain pure and active proteins from Lactococcus lactis protein aggregates , 2018, Scientific Reports.

[9]  E. Vázquez,et al.  Release of targeted protein nanoparticles from functional bacterial amyloids: A death star‐like approach , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Esther Vázquez,et al.  Bacterial Inclusion Bodies: Discovering Their Better Half. , 2017, Trends in biochemical sciences.

[11]  E. Garcia-Fruitós,et al.  Trends in recombinant protein use in animal production , 2017, Microbial Cell Factories.

[12]  E. Vázquez,et al.  Engineering tumor cell targeting in nanoscale amyloidal materials , 2017, Nanotechnology.

[13]  A. Villaverde,et al.  Nanostructured recombinant cytokines: A highly stable alternative to short-lived prophylactics. , 2016, Biomaterials.

[14]  E. Vázquez,et al.  Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs , 2016, Scientific Reports.

[15]  A. Villaverde,et al.  Complex Particulate Biomaterials as Immunostimulant-Delivery Platforms , 2016, PloS one.

[16]  J. Veciana,et al.  Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. , 2016, Acta biomaterialia.

[17]  Anna Huttenlocher,et al.  Neutrophil migration in infection and wound repair: going forward in reverse , 2016, Nature Reviews Immunology.

[18]  Esther Vázquez,et al.  Recombinant pharmaceuticals from microbial cells: a 2015 update , 2016, Microbial Cell Factories.

[19]  Antonio Villaverde,et al.  Functional protein aggregates: just the tip of the iceberg. , 2015, Nanomedicine.

[20]  J. Veciana,et al.  Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. , 2015, Nanomedicine.

[21]  U. Rinas,et al.  Improving protein delivery of fibroblast growth factor-2 from bacterial inclusion bodies used as cell culture substrates. , 2014, Acta biomaterialia.

[22]  S. Michaeli,et al.  Intradermal air pouch leukocytosis as an in vivo test for nanoparticles , 2013, International journal of nanomedicine.

[23]  P. E. Van den Steen,et al.  Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade , 2013, Critical reviews in biochemistry and molecular biology.

[24]  G. Opdenakker,et al.  Zymography methods for visualizing hydrolytic enzymes , 2013, Nature Methods.

[25]  Antonio Villaverde,et al.  The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. , 2010, Biomaterials.

[26]  J. Veciana,et al.  Surface Cell Growth Engineering Assisted by a Novel Bacterial Nanomaterial , 2009 .

[27]  Antonio Villaverde,et al.  Recombinant protein solubility—does more mean better? , 2007, Nature Biotechnology.

[28]  P. E. Van den Steen,et al.  Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins , 2007, Journal of leukocyte biology.

[29]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[30]  R. Dwek,et al.  The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors* , 2006, Journal of Biological Chemistry.

[31]  B. Plytycz,et al.  Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis. , 2006, Immunobiology.

[32]  C. Henkel,et al.  Inhibition of hepatic fibrogenesis by matrix metalloproteinase‐9 mutants in mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  A. Sali,et al.  Comparative protein structure modeling of genes and genomes. , 2000, Annual review of biophysics and biomolecular structure.

[34]  C. Janson,et al.  Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. , 2002, Acta crystallographica. Section D, Biological crystallography.

[35]  A. Henney,et al.  Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. , 2002, Journal of molecular biology.

[36]  R. Sciot,et al.  Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. , 1999, The Journal of clinical investigation.

[37]  J. Veciana,et al.  Functional protein-based nanomaterial produced in GRAS microorganism: a new platform for biotechnology , 2017 .

[38]  David E. Golan,et al.  Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.